Over the course of 7 days, DPA engaged 120 patient representatives from 52 countries to explore new approaches and propose new frameworks for collaboration. Sessions on finding alternative methods of fundraising, capacity building, and providing an update on clinical trials and COVID impact were followed by a discussion on drug development pipelines.
The broader rare neuromuscular community was invited to join the first three days. DPA facilitated discussion among all stakeholders to explore new approaches and propose new frameworks for collaboration. The online format enabled participation of young adults with Duchenne.
To see the full press release click here